Trials / Completed

CompletedNCT00747734

A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 35 (actual)

Sponsor: Genentech, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

Conditions

Solid Cancers

Interventions

Type	Name	Description
DRUG	MNRP1685A	Escalating intravenous dose

Timeline

Start date: 2008-09-01
First posted: 2008-09-05
Last updated: 2011-04-20

Source: ClinicalTrials.gov record NCT00747734. Inclusion in this directory is not an endorsement.